Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 1 Oral treatment with a novel first-in-class anti-fibrotic compound PBI-4050 reduces hepatic.

Slides:



Advertisements
Similar presentations
NORMAL LIVER Bile duct Hepatic arteriole Portal vein.
Advertisements

Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA Telephone: A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH.
Diseases of liver. By the end of the session the student should be able to: Discuss the components of the liver Discuss the components of the liver Discuss.
Liver Pathology, CASE 2 53 year-old with chronic alcohol and drug abuse who has been in numerous rehabilitation facilities in the past now presents with.
PATHOPHYSIOLOGY PATHOPHYSIOLOGY w DEFINED Involves the study of function that results from disease processes.
Liver and pancreas SYLLABUS: RBP(Robbins Basic Pathology) Chapters: The Liver and the Biliary Tract The Pancreas.
Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.
LIVER CIRRHOSIS. Liver cirrhosis  Define Cirrhosis.  Recognize the types of cirrhosis.  Recognize the major causes and the pathogenetic mechanisms.
Hepatobiliary system Integrated practical
三重大学医学部病理 Deficiency of tenascin-C attenuates liver
Integrated practical Dr Shaesta Naseem
Hepatitis. Hepatitis * Definition: Hepatitis is necro-inflammatory liver disease characterized by the presence of inflammatory cells in in the portal.
PATHOLOGICAL STUDIES ON INDUCED HEPATIC CIRRHOSIS WITH EVALUATION OF SOME HEPATOPROTECTIVE MATERIALS IN RATS PhD 2016.
CHRONIC SPECIFIC INFLAMMATION
Hepatobiliary system Pathology Dept, KSU GIT Block.
Alcoholic liver disease
Acute viral hepatitis There is disruption of lobular architecture, inflammatory cells in the portal tracts & sinusoids, and hepatocellular apoptosis (arrow).
Date of download: 7/3/2016 From: Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med. 2000;133(4): doi: /
Patterns of Hepatic Injury
Effects of Myrtus communis extract treatment in bile duct ligated rats
Liver cirrhosis.
A promising target for NASH
Volume 12, Issue 1, Pages (February 2010)
Digestive pathology 2.
Volume 16, Issue 5, Pages (November 2012)
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
Toxic responses of the liver
Acute hepatitis induced by greater celandine (Chelidonium majus)
Kester Crosse, Onuora G. Umeadi, Frank A
Y. Huang, X.-F. Tian, X.-G. Fan, C.-Y. Fu, C. Zhu 
Radioprotection of Lung Tissue by Soy Isoflavones
Volume 57, Issue 5, Pages (November 2012)
Volume 91, Issue 2, Pages (February 2017)
David A. Cano, Shigeki Sekine, Matthias Hebrok  Gastroenterology 
Volume 146, Issue 5, Pages e1 (May 2014)
Omega-3 fatty acids decreases oxidative stress, tumor necrosis factor-alpha, and interleukin-1 beta in hyperthyroidism-induced hepatic dysfunction rat.
Volume 137, Issue 4, Pages e5 (October 2009)
Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.
Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis  Jung-Yeon Kim, Hyun-Jin An, Woon-Hae.
Volume 129, Issue 5, Pages (November 2005)
Volume 42, Issue 4, Pages (April 2005)
Volume 114, Issue 3, Pages (March 1998)
Fig. 1. NASH and fibrosis develop late in mice fed an HFD.
Histological Assessment of the Sclerotic Graft-versus-Host Response in the Humanized RAG2−/−γc−/− Mouse Model  Marieke C.H. Hogenes, Suzanne van Dorp,
Volume 136, Issue 2, Pages (February 2009)
Volume 24, Issue 4, Pages (December 2017)
Volume 114, Issue 1, Pages (January 1998)
Volume 39, Issue 4, Pages (October 2003)
Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice  Zhi-Ming.
Approaches for treatment of liver fibrosis in chronic hepatitis C
Adequacy of Endoscopic Ultrasound Core Needle Biopsy Specimen of Nonmalignant Hepatic Parenchymal Disease  Ferga C. Gleeson, Amy C. Clayton, Lizhi Zhang,
Volume 16, Issue 5, Pages (November 2012)
Volume 125, Issue 6, Pages (December 2003)
Wilson Disease Mayo Clinic Proceedings
Nobuhiko Takahashi, Yong Qi, Hiral R. Patel, Rexford S. Ahima 
Volume 39, Issue 5, Pages (November 2003)
Volume 89, Issue 2, Pages (February 2016)
Volume 39, Issue 1, Pages (July 2003)
Volume 16, Issue 1, Pages (July 2012)
Volume 39, Issue 5, Pages (November 2003)
Volume 79, Issue 10, Pages (May 2011)
Volume 20, Issue 1, Pages (July 2014)
Volume 127, Issue 3, Pages (September 2004)
Volume 44, Issue 2, Pages (February 2006)
Fibrosis and alcohol-related liver disease
Toxic responses of the liver
RESULTS INTRODUCTION aim METHOD conclusions references
Liver fibrosis after CCl4 injury in 5αR1-KO and WT mice.
A B Figure S1, Effect of CH diet consumption for six weeks on mice hepatic morphology. Representative histologic microphotographs of H&E stained liver.
a b c Supplementary Figure 1
Presentation transcript:

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, Oral treatment with a novel first-in-class anti-fibrotic compound PBI-4050 reduces hepatic steatosis and improves kidney function in the diabetic db/db mouse model. 1 Presented by: Dr. Lyne Gagnon AASLD Conference Washington November 2-4, 2013 Disclosure: ProMetic BioSciences Inc. Additional Information Also including the results on the effect of PBI-4050 in CCl 4 -induced liver fibrosis

2

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 preclinical data in two liver fibrosis models 3 NASH-fibrosis model CCl 4 -induced steatohepatitis (Slides 17-27) Chronic model Uni-nephrectomized diabetic (db/db) mouse model (Slides 4-16)

Chronic model: Uni-nephrectomized diabetic (db/db) mouse model 4

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 reduces serum glucose to the C57BL/6 and sham level 5 Serum glucose measured on 5-hour starved mice

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 Treatment with PBI-4050 increases glucose metabolism in oral glucose tolerance test at day Serum glucose measured on 16-hour starved mice

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 reduces liver steatosis Liver Steatosis Db/dbDb/db + PBI-4050 p = 0.04

8 PBI-4050 reduces liver steatosis C57BL/6Db/dbDb/db + PBI

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 reduces fibrotic markers expression in liver 9

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 Treatment with PBI-4050 reduces kidney hyperfiltration in db/db mice at day 97 10

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 Treatment with PBI-4050 reduces proteinuria 11

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 Treatment with PBI-4050 increases urinary creatinine excretion 12

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 reduces kidney mesangium lesions 13

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 reduces fibrotic markers expression in kidney 14

15 PBI-4050 reduces lipid peroxidation in kidney

Conclusions: PBI-4050 offers the potential as a novel therapy for hepatic steatosis in DKD 16 In liver  Reduces steatosis  Reduces fibrotic markers (TGF- , collagen 1, MMP-2 and TIMP-1 mRNA expression) In kidney  Reduces kidney hyperfiltration, proteinuria, albuminuria  Increases urinary creatinine excretion  Reduces histological lesions in the mesangium  Reduces fibrotic markers expression (IL-6, collagen 1, TIMP-1 and MMP-2 mRNA expression)  Reduces oxidative stress (lipid peroxidation) PBI-4050 has now enter into clinical program.

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, NASH-Fibrosis Model CCl 4 -induced steatohepatitis 17

CCl 4 -induced liver fibrosis: Effect of PBI-4050 Study design Day 1: Oral administration of vehicle or PBI-4050 (day 1 to day 59) IP injection of 2ml/kg of CCl4 10% in olive oil, twice a week for 8, 12 or 16 weeks Day 59: Euthanasia and analysis C57BL6/J male 18

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 Day 59: Evidence of pre-fibrosis  The effect of PBI-4050 was studied on the pre-fibrosis/ fibrosis development in CCl 4 -induced hepatic fibrosis.  Fibrosis was estimated with the measurement of hydroxyproline which is a direct measure of collagen (marker of fibrosis) in the liver (next slide). PBI-4050 reduces liver fibrosis. 19

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces hepatic concentration of hydroxyproline 20 P = 0.007

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces the histology activity index (HAI)-Knodell score  Intoxication with CCl 4 results in hepatocyte damage, necrosis, inflammation, and fibrosis, which spreads to link the vascular structures that feed into and drain the hepatic sinusoid (the portal tract and central vein radicle, respectively), and over 8-30 weeks results in the development of fibrosis to hepatocellular carcinoma.  Knodell score is the combined scores for necrosis, inflammation and fibrosis. Histology activity index (HAI) evaluates: 1)Periportal +/- bridging necrosis (bridging between portal-portal and portal-central linkage); 2)Intralobular degeneration (acidophil bodies, ballooning, focal necrosis- scattered foci of hepatocellular necrosis) and focal necrosis; 3)Portal inflammation, and 4)fibrosis (fibrous portal expansion, or bridging fibrosis (portal-portal or portal-central linkage or cirrhosis (loss of normal hepatic lobular architecture with fibrous septae separating and surrounding nodules)). 21

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces the histology activity index (HAI)-Knodell score 22 p= 0.008

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces the collagen score in liver (Masson’sTrichrome staining) 23 p = 0.03

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces collagene deposition in CCl 4 -induced liver fibrosis (Masson’s trichrome stain)  The Masson’s trichrome stain the cytoplasm, keratin, muscle fibers and intracellular fibers in red colour; nuclei in black colour and collagen (fibrous tissue) in blue color.  All control mice revealed a normal distribution of collagen.  Extensive collagen deposition and bridging fibrosis were evident in CCl 4 -treated animals.  Significant reduction of collagen deposition and bridging formation between portal-portal or portal- central was observed in PBI-4050 treated animals. 24

25 Control CCL4) CCL4 CCL4 + PBI-4050 (200 mg/kg) PBI-4050 significantly reduces histological lesions in CCl 4 -induced liver fibrosis (Masson’s Trichrome)

Program Number TO021 – 50 th ERA-EDTA Congress – May 21, 2013 PBI-4050 significantly reduces histological lesions in CCl 4 -induced liver fibrosis (Hematoxylin-Eosin stain)  The hematoxylin eosin stains the cytoplasm in red colour; nuclei with blue colour and show the steatosis and lymphocyte infiltration in stained tissue.  A moderate steatosis and a severe inflammation are observed as compared to control (non-CCl 4 ) mice. Treatment with PBI-4050 reduces inflammatory infiltration in hepatic lobes. 26

27 Control CCL4) CCL4 CCL4 + PBI-4050 (200 mg/kg) PBI-4050 significantly reduces histological lesions in CCl 4 -induced liver fibrosis (Hematoxyline-Eosin)

28 Acknowledgements Biology Dr. Brigitte Grouix Lilianne Geerts François Sarra-Bournet Kathy Hince André Doucet Mikaël Tremblay Alexandra Felton Dr. Martin Leduc Liette Gervais Chemistry Dr. Christopher Penney Dr. Boulos Zacharie Dr. Shaun Abbott Jean-Simon Duceppe Frank Cesari Lyne Marcil Pierre Laurin